Matthew F. Brown

5.2k citations

38 papers · 1.5k indexed · h-index 20

Gastroenterology top 1%
- Gastrointestinal Tumor Research and Treatment 5
Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria 4
Oncology top 10%
- Chemokine receptors and signaling 4
Pulmonary and Respiratory Medicine top 10%
Hematology top 10%
Organic Chemistry
- Synthetic Organic Chemistry Methods 5
- Cyclopropane Reaction Mechanisms 3
- Catalytic Alkyne Reactions 3
Genetics
- Bacterial Genetics and Biotechnology 4
Molecular Biology
- Protein Degradation and Inhibitors 3

Co-authors: Daniel F. Harvey Ronald P. Gladue Maria Dêbiec‐Rychter Adam B. Salmon Robert D. Pates James M. Beach Samuel H. Zwillich T. S. Wiedmann
Cited by: Gastroenterology Molecular Medicine Oncology
Journals: Journal of the American Chemical Society (1 paper)Journal of Biological Chemistry (1 paper)Nature Communications (1 paper)
Partner nations: United States United Kingdom China

In The Last Decade

Matthew F. Brown

36 papers receiving 1.5k citations

Peers

Countries citing papers authored by Matthew F. Brown

Since Specialization

Citations

This map shows the geographic impact of Matthew F. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew F. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew F. Brown more than expected).

Fields of papers citing papers by Matthew F. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew F. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew F. Brown. The network helps show where Matthew F. Brown may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew F. Brown, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew F. Brown Line = papers co-authored together Matthew F. Brown links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Delivering on the promise of protein degraders Nature Reviews Drug Discovery ·Matthew N. O’Brien,Suman Luthra,Matthew F. Brown,Derek W. Bartlett	2023	60
2	Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes Nature Chemical Biology ·James Schiemer,Reto Horst,Yilin Meng,Justin I. Montgomery,Yingrong Xu,Xidong Feng,Kris A. Borzilleri,Daniel P. Uccello,Carolyn A. Leverett,Stephen Brown,Ye Che,Matthew F. Brown,Matthew M. Hayward,A. Gilbert,Mark C. Noe,Matthew F. Calabrese	2020	83
3	Hydropathy Patterning Complements Charge Patterning to Describe Conformational Preferences of Disordered Proteins The Journal of Physical Chemistry Letters ·Wenwei Zheng,Gregory L. Dignon,Matthew F. Brown,Young C. Kim,Jeetain Mittal	2020	81
4	Process Development for the Synthesis of Monocyclic β-Lactam Core 17 Organic Process Research & Development ·Manjinder S. Lall,Yong Tao,Joel T. Arcari,David C. Boyles,Matthew F. Brown,David B. Damon,Susan C. Lilley,Mark J. Mitton‐Fry,Jeremy T. Starr,A. Morgan Stewart,Jianmin Sun	2018	12
5	Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example Molecular Cancer Therapeutics ·Iris Eke,Adeola Y. Makinde,Molykutty J. Aryankalayil,Veit Sandfort,Sanjeewani T. Palayoor,Barbara H. Rath,Lance A. Liotta,Mariaelena Pierobon,Emanuel F. Petricoin,Matthew F. Brown,Jayne M. Stommel,Mansoor M. Ahmed,C. Norman Coleman	2017	26
6	Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms Drug Metabolism and Disposition ·Louis Leung,Xin Yang,Timothy J. Strelevitz,Justin I. Montgomery,Matthew F. Brown,Michael Zientek,Christopher Banfield,A. Gilbert,Atli Thorarensen,Martin E. Dowty	2016	25
7	Loss of Caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis Cell Death and Disease ·Matthew F. Brown,Brian J. Leibowitz,D Chen,Kan He,Fangdong Zou,Robert W. Sobol,Donna Beer–Stolz,Lin Zhang,Jian Yu	2015	40
8	Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors Cancer Research ·Sergei Boichuk,Derek J. Lee,Keith R. Mehalek,Kathleen R. Makielski,Agnieszka Woźniak,Danushka S. Seneviratne,Nina Korzeniewski,Rolando Cuevas,Joshua A. Parry,Matthew F. Brown,James P. Zewe,Takahiro Taguchi,Shin-Fan Kuan,Patrick Schöffski,Maria Dêbiec‐Rychter,Anette Duensing	2014	37
9	Siderophore Receptor-Mediated Uptake of Lactivicin Analogues in Gram-Negative Bacteria Journal of Medicinal Chemistry ·Jeremy T. Starr,Matthew F. Brown,Lisa Aschenbrenner,Nicole Caspers,Ye Che,Brian S. Gerstenberger,Michael D. Huband,John D. Knafels,M. Megan Lemmon,Chao Li,Sandra P. McCurdy,Eric B. McElroy,Mark R. Rauckhorst,Andrew P. Tomaras,Jennifer A. Young,Richard P. Zaniewski,Veerabahu Shanmugasundaram,Seungil Han	2014	46
10	The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA PLoS ONE ·Jing Sun,Quanhong Sun,Matthew F. Brown,Crissy Dudgeon,Julie Chandler,Xiang Xu,Yongqian Shu,Lin Zhang,Jian Yu	2012	40
11	A medium-throughput compound screen identifies novel treatment options for gastrointestinal stromal tumors (GIST) Sergei Boichuk,D.J. Lee,Keith R. Mehalek,Kathleen R. Makielski,Agnieszka Woźniak,Nina Korzeniewski,Rolando Cuevas,James P. Zewe,Shih–Fan Kuan,D.S. Sevevaratne,Matthew F. Brown,Takahiro Taguchi,Patrick Schöffski,Maria Dêbiec‐Rychter,Anette Duensing	2012	1
12	Structure–activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor Bioorganic & Medicinal Chemistry Letters ·Amy S. Antipas,Laura C. Blumberg,William H. Brissette,Matthew F. Brown,Jeffrey Casavant,Jonathan L. Doty,James P. Driscoll,Thomas M. Harris,Christopher S. Jones,Sandra P. McCurdy,Eric B. McElroy,Mark J. Mitton‐Fry,Michael J. Munchhof,David A. Reim,Lawrence A. Reiter,Sharon L. Ripp,Andrei Shavnya,Marc I. Smeets,Kristen A. Trevena	2010	7
13	CCR1 Antagonists: What Have We Learned From Clinical Trials Current Topics in Medicinal Chemistry ·Ronald P. Gladue,Matthew F. Brown,Samuel H. Zwillich	2010	65
14	Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells Cancer Research ·Sebastian Bauer,Joshua A. Parry,Thomas Mühlenberg,Matthew F. Brown,Danushka S. Seneviratne,Payel Chatterjee,Anna Chin,Brian P. Rubin,Shih-Fan Kuan,Jonathan A. Fletcher,Stefan Duensing,Anette Duensing	2009	34
15	Process Development of CP-481715, a Novel CCR1 Antagonist Organic Process Research & Development ·Bryan Li,Brian M. Andresen,Matthew F. Brown,Richard A. Buzon,Charles K.‐F. Chiu,Michel Couturier,Eric L. Dias,Frank J. Urban,V. John Jasys,John C. Kath,William S. Kissel,Tung Le,Z. Jane Li,Joanna T. Negri,Christopher S. Poss,John L. Tucker,David C. Whritenour,Kathleen S. Zandi	2005	9
16	Potent small molecule CCR1 antagonists Bioorganic & Medicinal Chemistry Letters ·John C. Kath,William H. Brissette,Matthew F. Brown,Maryrose J. Conklyn,Amy P DiRico,Peter H. Dorff,Ronald P. Gladue,Brett M. Lillie,Paul D. Lira,Erin N Mairs,William H. Martin,Eric B. McElroy,Molly A. McGlynn,Timothy Paradis,Christopher S. Poss,Ingrid A. Stock,Laurie Tylaska,Deye Zheng	2004	17
17	CP-481,715, a Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases Journal of Biological Chemistry ·Ronald P. Gladue,Laurie Tylaska,William H. Brissette,Paul D. Lira,John C. Kath,Christopher S. Poss,Matthew F. Brown,Timothy Paradis,Maryrose J. Conklyn,Kevin T. Ogborne,Molly A. McGlynn,Brett M. Lillie,Amy P DiRico,Erin N Mairs,Eric B. McElroy,William H. Martin,Ingrid A. Stock,Richard M. Shepard,Henry J. Showell,Kuldeep Neote	2003	59
18	N-carbamoyl analogs of zafirlukast: Potent receptor antagonists of leukotriene D4 Bioorganic & Medicinal Chemistry Letters ·Matthew F. Brown,Anthony Marfat,G.W. Antognoli,Robert Chambers,John B. Cheng,David B. Damon,Theodore E. Liston,Molly A. McGlynn,Stacie P. O'Sullivan,Brian S. Owens,Joann S. Pillar,John T. Shirley,J. W. Watson	1998	4
19	Molybdenum carbene complexes: Cyclopropanation of electron-poor olefins Tetrahedron Letters ·Daniel F. Harvey,Matthew F. Brown	1990	44
20	Lipid-protein interactions mediate the photochemical function of rhodopsin Biochemistry ·T. S. Wiedmann,Robert D. Pates,James M. Beach,Adam B. Salmon,Matthew F. Brown	1988	136

About Matthew F. Brown

Matthew F. Brown is a scholar working on Gastroenterology, Molecular Medicine and Oncology, having authored 38 papers that have together received 1.5k indexed citations. Recurring topics across this work include Gastrointestinal Tumor Research and Treatment (5 papers), Synthetic Organic Chemistry Methods (5 papers), Antibiotic Resistance in Bacteria (4 papers), Chemokine receptors and signaling (4 papers), Bacterial Genetics and Biotechnology (4 papers), Cyclopropane Reaction Mechanisms (3 papers), Catalytic Alkyne Reactions (3 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Gastroenterology (346 citations), Molecular Medicine (140 citations) and Oncology (302 citations). Matthew F. Brown has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Daniel F. Harvey, Ronald P. Gladue, Maria Dêbiec‐Rychter, Adam B. Salmon, Robert D. Pates, James M. Beach, Samuel H. Zwillich, T. S. Wiedmann, Michel Stul and Bartosz Wasąg. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact